Wolfe Research upgraded Edwards Lifesciences Corp (EW) to Peer Perform from Underperform on October 28, 2025. The current share price stands at $85.14.
This upgrade reflects a more optimistic outlook on the company's prospects, potentially indicating improved fundamentals or better-than-expected business performance. Edwards Lifesciences, headquartered in Irvine, California, specializes in patient-focused medical innovations for heart disease and critical care monitoring. The firm employs 15,800 full-time staff and has a market capitalization of $47.9 billion.
For context, Edwards Lifesciences has a trailing twelve-month price-to-earnings ratio of 35.00 and earnings per share of $2.33. The company is set to report its next earnings on July 21, 2026, with estimates of $0.74 EPS and $1.7 billion in revenue.
Analyst consensus as of November 1, 2025, includes 10 Strong Buy, 18 Buy, and 15 Hold ratings, reflecting a general positive sentiment towards the stock. Recent analyst actions include upgrades from Jefferies to Buy and from Evercore ISI Group to Outperform, indicating a trend of increasing confidence in the company's performance.
This update provides insight into the evolving analyst sentiment surrounding Edwards Lifesciences, which focuses on critical areas such as Transcatheter Aortic Valve Replacement and other innovative heart therapies.